<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;div class="table-responsive"&gt;&lt;table class="table table-bordered align-top" border="1" summary="Meeting data"&gt;&lt;thead&gt;&lt;tr&gt;&lt;th bgcolor="#cccccc" scope="col"&gt;Center&lt;/th&gt;&lt;th bgcolor="#cccccc" scope="col"&gt;Date&lt;/th&gt;&lt;th bgcolor="#cccccc" scope="col"&gt;Time&lt;/th&gt;&lt;th bgcolor="#cccccc" scope="col"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;CBER&lt;/td&gt;&lt;td&gt;May 13, 2015&lt;/td&gt;&lt;td&gt;May 13, 2015 from 8:00 a.m. to approximately 5:30 p.m.&lt;/td&gt;&lt;td&gt;10903 New Hampshire Avenue.,&lt;br /&gt;Building 31 Conference Center,&lt;br /&gt;The Great Room, room 1503.&lt;br /&gt;Silver Spring, MD 20993-0002&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;br /&gt;On May 13, 2015, the Committee will meet in open session to discuss strategies for implementation of serological and nucleic acid testing for &lt;em&gt;Babesia microtiin&lt;/em&gt; blood donors. In the afternoon, the committee will hear update presentations on the following topics: 1) FDA considerations for Hemoglobin S Testing in blood donors; and 2) FDA considerations for a revised blood donor deferral policy for men who have sex with men.&amp;nbsp; Following the update presentations, the committee will hear presentations on the research programs of the Laboratory of Cellular Hematology, Division of Hematology Research and Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research, FDA.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Meeting Materials&lt;/strong&gt;&lt;br /&gt;Materials for this meeting will be available at the&amp;nbsp;&lt;a target="" href="[!--$wcmUrl('nodelink','2062')--]"&gt;Blood Products Advisory Committee Meeting main page&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Public Participation Information&lt;/strong&gt;&lt;br /&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul type="disc"&gt;&lt;li&gt;Written submissions may be made to the contact person on or before May 6, 2015&lt;/li&gt;&lt;li&gt;Oral presentations on May 13, 2015 from the public will be scheduled between approximately 11:15 a.m. and 12:15 p.m. and 4:30 p.m. and 5:00 p.m.&lt;/li&gt;&lt;li&gt;Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before April 28, 2015.&amp;nbsp;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by April 29, 2015.&lt;/li&gt;&lt;li&gt;For those unable to attend in person, the meeting will also be Web cast.&amp;nbsp;The Web cast will be available at the following link.&lt;br /&gt;Blood Products Advisory Committee meeting May 13, 2015: &lt;a href="https://collaboration.fda.gov/bpac2015/"&gt;https://collaboration.fda.gov/bpac2015/&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Bryan Emery or Joanne Lipkind&lt;br /&gt;10903 New Hampshire Ave.,&lt;br /&gt;Bldg. 71, rm. 6132,&lt;br /&gt;Silver Spring, MD 20993-0002,&lt;br /&gt;240-402-8054&lt;br /&gt;e-mail: &lt;a href="mailto:Bryan.Emery@fda.hhs.gov"&gt;Bryan.Emery@fda.hhs.gov&lt;/a&gt; or email: &lt;a href="mailto:Joanne.Lipkind@fda.hhs.gov"&gt;Joanne.Lipkind@fda.hhs.gov&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138 (301-443-0572 in the Washington, DC, area). Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. Seating for this meeting may be limited, so the public is encouraged to watch the free webcast if you are unable to attend.&amp;nbsp;The link for the webcast will be available at 8 a.m. May 13, 2015 at the links above.&amp;nbsp;FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Bryan Emery or Joanne Lipkind at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site&amp;nbsp;for &lt;a target="" href="[!--$wcmUrl('link','UCM111462')--]"&gt;procedures on public conduct during advisory committee meetings&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). &lt;a target="_blank" href="[!--$ssExternalLink('UCM441241')--]"&gt;Official FR Notice&lt;/a&gt;&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
